The risk of interstitial radiotherapy of low-grade gliomas.
OBJECTIVE
The risk of side effects of low activity (i.e. <20 mCi) Iodine-125I (125I) interstitial radiotherapy was analyzed in patients with low-grade gliomas.


METHODS
Permanent (247 patients) or temporary 125I-implants (268 patients) were used with a median reference dose of 60 Gy and 100 Gy, respectively, which was calculated to the outer rim of the tumour. The mean dose rate for temporary implants was low (median, 10 cGy/h). Risk factors were obtained from the multivariate proportional-hazards model.


RESULTS
Radiogenic complications occurred in 39/515 patients (28 patients with transient symptoms and 11 patients with progressive symptoms). The most important risk factor was the volume of the intratumoural 200 Gy isodose. Available experimental data have associated a high dose zone in this range with the size of the treatment induced radionecrosis. Rapid tumour shrinkage (decrease of the tumour volume > or =50%) within the first 6 months with subsequent centripetal movement of non-pathologic tissue into the high dose zone and a reimplantation were additional risk factors. Radiation injury after rapid tumour shrinkage could be better avoided with temporary implants. A 200 Gy isodose volume <4.5 ml corresponded to an estimated risk of radiogenic complications <3%. There was a steep increase of the risk beyond this limit. Translation of the 200 Gy isodose volume in terms of the treatment volume and the reference dose allows rational treatment planning. The estimated risk of a temporary implant with an applied reference dose of 60 Gy and a treatment volume <23 ml was <3%.


CONCLUSIONS
The intratumoural necrotizing effect of a low activity 125I implant limits its application to small treatment volumes. Radiation injury outside the treatment volume can be better avoided with temporary implants in the case of rapid tumour shrinkage.
Kreth
F W
FW
Abteilung Stereotaktische Neurochirurgie, Freiburg, Germany.
Faist
M
M
Rossner
R
R
Birg
W
W
Volk
B
B
Ostertag
C B
CB
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001918:Brachytherapy / Q000009:adverse effects*; D001927:Brain Diseases / Q000209:etiology; D001932:Brain Neoplasms / Q000473:pathology* / Q000532:radiotherapy*; D003560:Cysts / Q000209:etiology; D005260:Female; D005910:Glioma / Q000473:pathology* / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011832:Radiation Injuries / Q000209:etiology; D012307:Risk Factors
D007457:Iodine Radioisotopes